AlgiPharma is Recruiting

AlgiPharma announces two new positions avaliable.

AlgiPharma is interested to hear from high caliber, energetic candidates to join the team at our Norwegian office in Sandvika. Preference will be given to those candidates already resident in Norway or who are already eligible to work in Norway. The deadline for applications is the 12th May 2019 (see local press advertisement for details on how to submit).

R&D Project Manager

The candidate will proactively manage the day to day running of multiple R&D projects, coordinating with key internal and external stakeholders to advance our portfolio of products for cystic fibrosis, respiratory, wound healing, and other indications based on our alginate oligomer technology. Focused on development of new indications the candidate will develop these project to proof-of-concept (POC) studies in man and cooperate with colleagues and external parties to initiate these studies. The candidate will work collaboratively with a focus on effective planning, coordination of activities, and efficient implementation of R&D strategy. This will include working with external academic and clinical partners, Contract Research Organizations (CROs) and suppliers. The candidate will have demonstrated clear organizational skills and experience of project management in the biotech/biopharma industry, and have relevant experience in R&D and chemical/biotechnological manufacturing. Previous experience establishing effective working relationships in a virtual organization is an asset. The candidate will report directly to the Chief Scientific Officer.

The ideal candidate has:

  • PhD in biological science or a related field.
  • 5+ years’ experience as a Project Manager.
  • Experience in managing multiple project accounts and familiarity applying to funding agencies and reporting on project grants.
  • Experience of project management in the biotechnology or pharmaceutical industry.
  • Proficiency in Microsoft Office programs and tools.
  • Excellent communication and presentation skills in Norwegian and English.

Clinical Trial Manager

We are looking for a well-organized, detail-oriented and flexible candidate to join the clinical team managing the daily operations in the progress of our clinical trials. The candidate will help develop and maintain documentation and materials for clinical trials, working closely with trial sites, and external CRO staff. The candidate will manage multiple aspects of running complex international multicenter trials, including site visits, generate and distribute internal and external reports and newsletters, and liaise with relevant parties regarding all trial aspects. The candidate will play a leading role in generating and overseeing documentation and records, and will work closely with other staff ensuring compliance with relevant guidelines. The candidate will report directly to the Clinical Director.

The ideal candidate has:

  • Bachelor’s degree or higher in biological science, medicine, pharmaceutical, nursing or a related field.
  • 3+ years’ experience as a Clinical Research Associate.
  • Knowledge of pharmaceutical industry, terminology and practices.
  • Knowledge of EU and FDA regulations and their practical implementation.
  • Excellent communication and presentation skills in Norwegian and English.
  • Proficiency in Microsoft Office programs and tools. Experience with commonly used IT tools for clinical trial data collection and analysis.
  • Ability to manage and prioritize workload effectively.
  • Available to travel extensively, and occasionally on short notice.

About AlgiPharma

AlgiPharma AS is dedicated to the development and commercialization of novel therapeutics, based on our patented alginate oligomer technology that will help transform the lives of patients with chronic diseases: Helping patients and their families towards a better day. www.algipharma.com – A better day

AlgiPharma is a clinical stage biopharmaceutical company with a primary focus on respiratory diseases and other conditions caused by microbial infections and biofilms. Our aim is to address unmet medical needs and fight diseases effectively through our innovative alginate technologies. Our alginate technology targets those diseases where there is a clinical need to mitigate abnormal mucus accumulation, microbial infection, biofilm formation and antibiotic resistance. AlgiPharma is developing its first drug candidate for patients with Cystic Fibrosis (CF), where we hold orphan drug status with EMA and FDA. To date we have won about NOK 300 million in Government and NGO support including NOK 120 million from the American Cystic Fibrosis Foundation. We have completed 5 clinical trials to date, and will be initiating 2 more phase 2b multinational trials this spring and summer. The AlgiPharma technology has multiple applications including other respiratory diseases such as COPD, infection, wound healing, and medical device coatings. Building on the success and exciting developments of our technology, the team at AlgiPharma is expanding to meet the demands of bringing our first drug candidate to market.

What we offer:

  • Engaging working environment at a dynamic company on the verge of delivering the first of its drug candidates to market.
  • Opportunity for self-development, such as training courses and/or conferences.
  • A dynamic working atmosphere.
  • Flexibly in working hours to maintain a good work-life balance.
  • Great health insurance plan.
  • Excellent remuneration package, including the opportunity to attend relevant training and education courses and congresses.

New 2b Clinical Trial started in Australia

New Phase 2b Clinical Trial:

A phase 2b, randomised, double-blind, study of alginate oligosaccharide (OligoG) dry powder inhalation on top of standard of care compared to placebo on top of standard of care in patients with Cystic Fibrosis (CF). (ORDCF-205)

A new clinical study was initiated with a Clinical Trial Investigator Meeting held on 29th March alongside the TSANZ conference in Gold Coast, Australia. The clinical trial is a randomised, double-blinded, controlled pilot study for proof of concept that an OligoG dry powder for inhalation formulation can improve lung function in adult CF patients.  Study medication will be given twice daily for twelve weeks on top of standard of care. Thirty-three patients will be included, out of which twenty-two shall receive OligoG, and eleven shall receive placebo. A 12 month open-label extension will be available to all patients who complete the 12 week blinded treatment study.


 

About Cystic Fibrosis:

Cystic fibrosis (CF) is a life-threatening disease that affects the lungs and digestive system and impacts about 70,000 people worldwide. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which results in either no CFTR protein or an abnormal CFTR protein that does not function properly. The presence or absence of this dysfunctional protein causes the body to accumulate excessive levels of unusually thick mucus in the lungs, which becomes a site for infections that can require hospitalization. Respiratory distress in CF (defined as acute difficulty in breathing, infection and/or hospitalization) is most commonly related to mucus accumulation and lung infections that result in damage to lung tissue.

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company with headquarters in Norway. It was founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis.

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 37 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, US Army through Congressional Earmark funding, and the Cystic Fibrosis Foundation (CFF). Please see latest award from CFF.

AlgiPharma is a privately owned company registered and domiciled in Norway.

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com

AlgiPharma Appoints Director for Australian Operations

AlgiPharma has appointed a new director Marieta Ryan to lead the recently established Australian office and to facilitate clinical trial operations in Australia. Marieta was officially appointed in mid-2018 and is actively involved in two of AlgiPharma’s multinational clinical phase 2b studies with clinical sites in Europe, Australia and New Zealand.

About Cystic Fibrosis:

Cystic fibrosis (CF) is a life-threatening disease that affects the lungs and digestive system and impacts about 70,000 people worldwide. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which results in either no CFTR protein or an abnormal CFTR protein that does not function properly. The presence or absence of this dysfunctional protein causes the body to accumulate excessive levels of unusually thick mucus in the lungs, which becomes a site for infections that can require hospitalization. Respiratory distress in CF (defined as acute difficulty in breathing, infection and/or hospitalization) is most commonly related to mucus accumulation and lung infections that result in damage to lung tissue.

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company with headquarters in Norway. It was founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis.

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 37 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, US Army through Congressional Earmark funding, and the Cystic Fibrosis Foundation (CFF). Please see latest award from CFF.

AlgiPharma is a privately owned company registered and domiciled in Norway.

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com

Innovation Award Winner for 2018

AlgiPharma registers new company in Australia

AlgiPharma has registered a new proprietary limited company in Melbourne, Australia:

AlgiPharma Australia Pty Ltd

AlgiPharma is moving ahead with its clinical program and preparations for a new phase 2b clinical trial with its drug candidate OligoG. Australia will be a key part of this pivotal study. The AlgiPharma team recognizes the value in establishing a strong presence in Australia to help bring its lead drug candidate, OligoG, to the market for the treatment of patients suffering with Cystic Fibrosis.

About Cystic Fibrosis:

Cystic fibrosis (CF) is a life-threatening disease that affects the lungs and digestive system and impacts about 70,000 people worldwide. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which results in either no CFTR protein or an abnormal CFTR protein that does not function properly. The presence or absence of this dysfunctional protein causes the body to accumulate excessive levels of unusually thick mucus in the lungs, which becomes a site for infections that can require hospitalization. Respiratory distress in CF (defined as acute difficulty in breathing, infection and/or hospitalization) is most commonly related to mucus accumulation and lung infections that result in damage to lung tissue.

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company with headquarters in Norway. It was founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis.

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 37 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, US Army through Congressional Earmark funding, and the Cystic Fibrosis Foundation (CFF). Please see latest award from CFF.

AlgiPharma is a privately owned company registered and domiciled in Norway.

 

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com

 

AlgiPharma’s Cystic Fibrosis drug candidate OligoG awarded pivotal trial grant of €6 million from EU’s Horizon 2020 programme

An EU Horizon 2020 proposal (OligoGpivotalCF) submitted by a consortium assembled by AlgiPharma, has been successful in winning a grant of EUR 6 million to support AlgiPharma’s cystic fibrosis drug candidate OligoG through a pivotal clinical trial program.

AlgiPharma receives up to an additional $3 million from the US Cystic Fibrosis Foundation (CFF)

AlgiPharma AS announced an agreement with Cystic Fibrosis Foundation (CFF), Bethesda, MD., that will provide up to $3 million to support further research and development of AlgiPharma’s drug candidate (OligoG) for the treatment of people with cystic fibrosis. This is in addition to more than $11.5 million already received from the Cystic Fibrosis Foundation for Phase 2 clinical work.

OligoG is an alginate oligosaccharide derived from seaweed, and is a new class of drug being developed to help people with cystic fibrosis clear stagnant and highly viscous mucus from their lungs. It is anticipated that OligoG will help to slow progression of the disease.

In a previous clinical 2b trial the primary efficacy endpoint (improved lung function as measured by FEV1, or forced expiratory volume in 1 second) was not achieved at 28 days across the entire study population. However, more detailed analyses showed that several subgroups demonstrated significant improvement in FEV1, showing more than 9% improvement in lung function by day 28, with further improvement in the subsequent washout period. A new clinical trial is being planned to optimize dosing to match these subgroups, which represent the majority of the CF patient population.

AlgiPharma has to date completed five clinical trials with a total safety population of 169 subjects, and has demonstrated an exemplary safety record.

Yngvar P. Berg, CEO of AlgiPharma, commented on the award: “We are honored and delighted that the Cystic Fibrosis Foundation recognizes the unique therapeutic potential of our drug candidate by further supporting the development of OligoG. The award from the CFF will be complementary to EUR 6 million from its EU Horizon 2020 grant (‘OligoGpivotalCF’) to perform a pivotal clinical trial program with OligoG. This CFF award enables us to accelerate the development of OligoG, and we really appreciate working with the Foundation on the remaining development path in bringing this new drug to people with cystic fibrosis.”

 

About Cystic Fibrosis:

Cystic fibrosis (CF) is a life-threatening disease that affects the lungs and digestive system and impacts about 70,000 people worldwide. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene which results in either no CFTR protein or an abnormal CFTR protein that does not function properly. The presence or absence of this dysfunctional protein causes the body to accumulate excessive levels of unusually thick mucus in the lungs, which becomes a site for infections that can require hospitalization. Respiratory distress in CF (defined as acute difficulty in breathing, infection and/or hospitalization) is most commonly related to mucus accumulation and lung infections that result in damage to lung tissue.

For more information on CF, please visit the individual websites at CFFECFS, CF-EUROPE

 

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis.

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 37 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, US Army through Congressional Earmark funding, and the Cystic Fibrosis Foundation (CFF). Please see latest award from CFF.

AlgiPharma is a privately owned company registered and domiciled in Norway.

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com

Click here for a pdf version of this press release.

 

AlgiPharma awarded 4 year grant from the Norwegian Research Council’s NANO2021 programme

AlgiPharma has been awarded up to NOK 10 million from the Norwegian Research Council for the project “Novel alginate oligomer products for enhanced delivery across mucosal barriers (Mucos-ALG)”.

The underlying idea for the project is to establish and optimize the design of alginate oligomers to enhance the delivery of drugs and small molecules across mucosal barriers. The project requires a combination of R&D skills and these requirements will be met through a consortium of international partners, many of whom have already worked successfully with AlgiPharma on previous R&D projects.

It is expected that the project will provide new alginate oligomer based products enabling more effective mucosal delivery for therapeutics in CF, COPD, infection and wound care.

 

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis.

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 37 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, US Army through Congressional Earmark funding, and the Cystic Fibrosis Foundation (CFF). Please see latest award from CFF.

AlgiPharma is a privately owned company registered and domiciled in Norway.

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com

Hilde Morris joins AlgiPharma

Hilde Morris has recently been appointed to replace our outgoing clinical director Dr. Astrid Hilde Myrset, who will continue in a consultancy in the short term to ensure a smooth transition of the role. Hilde Morris will take over the Cystic Fibrosis clinical development program at AlgiPharma. She is a veterinarian by training, and has previously held leading positions within clinical research in Nycomed-Imaging-Amersham-GE Healthcare, as well as in Photocure ASA, where she was VP of R&D until 2006. From 2007 to 2017. Hilde has worked as an independent consultant within the fields of clinical research regulatory affairs. She has had responsibility for coordinating multiple international clinical trial programs from phase I – IV for a wide range of pharmaceuticals in the US, EU and Australia, and has over 25 years’ experience interacting with international regulatory authorities.

AlgiPharma collaboration with Cardiff University wins Medical Innovation Award

A long standing collaboration between AlgiPharma and Professor David Thomas team at the School of Dentistry has been recognized this year by Cardiff University’s prestigious Medical Innovation Award. The award was presented by Dr. Rob Docherty on behalf of Cardiff University.

 

 

Click here for more information and link to the video

 

 

 

(Left to Right) Dr. Manon Pritchard (Cardiff), Dr. Phil Rye (AlgiPharma), Dr Rob Docherty (presenting the award), Prof. David Thomas (Cardiff), Dr. Katja Hill (Cardiff), Dr. Saira Khan (Cardiff), Mr Arne Dessen (AlgiPharma), Dr. Lydia Powell (Cardiff).